ABSTRACT

The aim of this study is to develop, evaluate, and validate Piroxicam and Venlafaxine in bulk and market formulations. The separation was carried out by using Hypersil BDS column (250x4.6,5?m) at ambient temperature to develop this method. Acetonitrile, Methanol, and ammonium acetate buffer(C?H?NO?) (40:30:30 v/v/v) were fed into the column at a flow rate of 1.0 mL/min at a wavelength of 234nm. Piroxicam and venlafaxine reported linearity concentrations of 10-50?g/ml and 100-200?g/ml, respectively, with correlation coefficients (R2) of 0.9990 and 0.9991. With % RSD values of NMT 2.0, the approach was verified to be precise. The results revealed that the procedure was accurate, with a % recovery of 99.74% for Piroxicam and 100.04 % for Venlafaxine. The ICH guidelines Q2 (R1) were utilized to validate this method. All parameters, including theoretical plates, resolution, tailing factor, and percent RSD, were within acceptable ranges. The selected two drugs piroxicam, venlafaxine was not estimated in combination earlier. As a result, the focus of this analysis is a modest, innovative rapid analytical procedure. As a result, the proposed method can be used on a routine basis. Keywords: Piroxicam, Venlafaxine, HPLC, ICH
Publication date: 01/08/2023

https://ijbpas.com/pdf/2023/August/MS_IJBPAS_2023_7351.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.8.7351